Literature DB >> 12243759

Deletion mutagenesis of the amino-terminal head domain of vimentin reveals dispensability of large internal regions for intermediate filament assembly and stability.

Robert L Shoeman1, Roland Hartig, Monika Berthel, Peter Traub.   

Abstract

Previous studies have shown that the non-alpha-helical head domain of vimentin is required for polymerization of intermediate filaments (IFs) and, furthermore, a nonapeptide highly conserved among type III IF subunit proteins at their extreme amino-terminus is essential for this process. Recombinant DNA technology was employed to produce specific vimentin deletion mutant proteins (for in vitro studies) or vimentin protein expression plasmids (for in vivo studies), which were used to identify other regions of the vimentin head domain important for polymerization. Various vimentin proteins lacking either residues 25-38, 44-95, or 40-95 polymerized into wild-type or largely normal IFs, both in vitro and in vivo. Vimentin proteins lacking residues 44-69 or 25-63 failed to form IFs in vitro, but assembled into IFs in vivo. Vimentin proteins lacking residues 25-68, 44-103, or 88-103 failed to form IFs in vitro or in vivo. Taken together with previous results, these data demonstrate that the middle of the vimentin non-alpha-helical head domain, which is known to be the site of nucleic acid binding, is completely dispensable for IF formation, whereas both ends of the vimentin non-alpha-helical head domain are required for IF formation. The simplest explanation for these results is that the middle of the vimentin non-alpha-helical head domain loops out, thereby permitting the juxtaposition of the ends of the head domain and their productive interaction with other protein domains (probably the C-terminus of the rod domain) during IF polymerization. The ability of some of the mutant proteins to form IFs in vivo, but not in vitro, suggests that as-yet-unknown cellular proteins may interact with and, in some cases, enable polymerization of IFs, even though they are not absolutely required for IF formation by wild-type vimentin.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12243759     DOI: 10.1006/excr.2002.5618

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  7 in total

1.  Site-directed spin labeling and electron paramagnetic resonance determination of vimentin head domain structure.

Authors:  Atya Aziz; John F Hess; Madhu S Budamagunta; John C Voss; Paul G FitzGerald
Journal:  J Biol Chem       Date:  2010-03-15       Impact factor: 5.157

2.  Impact of N-Terminal Tags on De Novo Vimentin Intermediate Filament Assembly.

Authors:  Saima Usman; Hebah Aldehlawi; Thuan Khanh Ngoc Nguyen; Muy-Teck Teh; Ahmad Waseem
Journal:  Int J Mol Sci       Date:  2022-06-06       Impact factor: 6.208

Review 3.  The "Third Violin" in the Cytoskeleton Orchestra-The Role of Intermediate Filaments in the Endothelial Cell's Life.

Authors:  Anton S Shakhov; Irina B Alieva
Journal:  Biomedicines       Date:  2022-04-01

4.  Identifying the role of specific motifs in the lens fiber cell specific intermediate filament phakosin.

Authors:  Joshua T Pittenger; John F Hess; Paul G Fitzgerald
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-11       Impact factor: 4.799

5.  Vimentin intermediate filaments modulate the motility of mitochondria.

Authors:  Oxana E Nekrasova; Melissa G Mendez; Ivan S Chernoivanenko; Pyotr A Tyurin-Kuzmin; Edward R Kuczmarski; Vladimir I Gelfand; Robert D Goldman; Alexander A Minin
Journal:  Mol Biol Cell       Date:  2011-05-11       Impact factor: 4.138

6.  The tail domain is essential but the head domain dispensable for C. elegans intermediate filament IFA-2 function.

Authors:  Kyle Williams; Kristen Williams; Hallie M Baucher; John Plenefisch
Journal:  PLoS One       Date:  2015-03-05       Impact factor: 3.240

7.  Site-specific glycosylation regulates the form and function of the intermediate filament cytoskeleton.

Authors:  Heather J Tarbet; Lee Dolat; Timothy J Smith; Brett M Condon; E Timothy O'Brien; Raphael H Valdivia; Michael Boyce
Journal:  Elife       Date:  2018-03-07       Impact factor: 8.140

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.